Ken Kato

30.3k citations
513 papers · 13.5k · 6 hit papers · h-index 57

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
  • Surgery top 0.1%
    • Esophageal Cancer Research and Treatment
    • Esophageal and GI Pathology

Papers in

    • Esophageal Cancer Research and Treatment 203
    • Esophageal and GI Pathology 29
    • Cancer Immunotherapy and Biomarkers 89
    • Colorectal Cancer Treatments and Studies 59
    • Pancreatic and Hepatic Oncology Research 27

Ken Kato

473 papers receiving 13.3k citations

Ken Kato's Hit Papers

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. 2022 · 130 citations
1300+3+6Years since publication250500750

Peers

Ken Kato
Comparison fields: 5 of 140
  • Oncology 3.8k
  • Surgery 5.2k
  • Pulmonary and Respiratory Medicine 3.0k
  • Cancer Research 1.4k
  • Gastroenterology 366
Replace Kosei Hirakawa with:
Kosei Hirakawa Japan
Jens Werner Germany
Kei Muro Japan
Takashi Aikou Japan
Thilo Hackert Germany
Eigo Otsuji Japan
Daniele Santini Italy
Yoshiharu Sakai Japan
Akimasa Nakao Japan
Atsushi Masamune Japan
Ken Kato relative to Kosei Hirakawa Japan Kosei Hirakawa's profile →
Citations per field
00.5×2.7×
Kosei Hirakawa · 1×
Citations per year

Countries citing papers authored by Ken Kato

Since Specialization
Citations

This map shows the geographic impact of Ken Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Kato more than expected).

Fields of papers citing papers by Ken Kato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Kato. The network helps show where Ken Kato may publish in the future.

Co-authors

The 25 scholars most cited alongside Ken Kato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ken Kato Line = papers co-authored together Ken Kato links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 513 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Hit paper breakdown →
2019786
2
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Hit paper breakdown →
2018412
3
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Hit paper breakdown →
2018376
4
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Hit paper breakdown →
2018365
5
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Hit paper breakdown →
2017294
6 2010271
7 2018238
8 2013233
9 2018231
10 2007213
11 2010189
12 2018183
13 2011172
14 2013167
15 2016166
16 2012160
17 2019157
18
Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen.
1999157
19 2009154
20 1999134

About Ken Kato

Ken Kato is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 513 papers that have together received 13.5k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (203 papers), Gastric Cancer Management and Outcomes (140 papers), Cancer Immunotherapy and Biomarkers (89 papers), Colorectal Cancer Treatments and Studies (59 papers), Lung Cancer Treatments and Mutations (40 papers), Esophageal and GI Pathology (29 papers), Pancreatic and Hepatic Oncology Research (27 papers) and Gastrointestinal Tumor Research and Treatment (23 papers). The work is most often cited by research in Oncology (3.8k citations), Surgery (5.2k citations), Pulmonary and Respiratory Medicine (3.0k citations), Cancer Research (1.4k citations) and Gastroenterology (366 citations). Ken Kato has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasuhide Yamada, Yuko Kitagawa, Yasuhiro Shimada, Tetsuya Hamaguchi, Takashi Kojima, Satoru Iwasa, Kei Muro, Yuichiro� Doki, Hiroyuki Daiko and Yasuo Hamamoto. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Esophagus, Japanese Journal of Clinical Oncology and Cancer Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact